Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085687233> ?p ?o ?g. }
- W2085687233 endingPage "257" @default.
- W2085687233 startingPage "249" @default.
- W2085687233 abstract "Interferon-alpha (IFN-alpha), a molecule with multiple biological actions, is widely used in the treatment of chronic myelogenous leukemia (CML) and the other myeloproliferative disorders. This glycoprotein belonging to the type I subfamily of interferons has been recombinantly manufactured and has been approved for the biotherapy of CML, now becoming the first line of treatment for CML patients in chronic phase who are not candidates for allogeneic hematopoietic stem cell or bone marrowtransplantation. Interferon-alpha action involves binding to its cell membrane receptor and initiation of an intracellular signal transduction cascade. Two major pathways mediate the biologic actions of IFN-alpha. The JAK-STAT pathway leads to phosphorylation and activation of STAT 1 and STAT 2 molecules and transcription of genes like p21 and caspase-1 resulting in cycle arrest and apoptosis. The PKR (protein kinase dsRNA-induced) kinase phosphorylates and inhibits the eukaryotic initiator of translation eIF-2alpha leading again to apoptosis. The PKR kinase cascade also leads to activation of the transcription factor NF-kappaB. The relevance of this activation is unclearand it is possiblethat NF-kappaB has not had the opportunity to transcribe its target genes as it is a substrate of effector caspases and is maybe cleaved by them before exerting any transcription activity. Through the JAK-STAT and the PKR kinase pathways IFN-alpha is able to modify the proliferative and antiapoptotic actions of the constitutively activated kinase bcr-abl, the product of the t(9;22) translocation present in CML, and has therapeutic effects in this disease." @default.
- W2085687233 created "2016-06-24" @default.
- W2085687233 creator A5005259160 @default.
- W2085687233 date "2000-08-01" @default.
- W2085687233 modified "2023-09-26" @default.
- W2085687233 title "Interferon-alpha and the pathogenesis of myeloproliferative disorders" @default.
- W2085687233 cites W116446150 @default.
- W2085687233 cites W12631990 @default.
- W2085687233 cites W131261646 @default.
- W2085687233 cites W1480179919 @default.
- W2085687233 cites W1484834653 @default.
- W2085687233 cites W1519361392 @default.
- W2085687233 cites W1562884473 @default.
- W2085687233 cites W1638465953 @default.
- W2085687233 cites W164957562 @default.
- W2085687233 cites W1719918577 @default.
- W2085687233 cites W1915631065 @default.
- W2085687233 cites W1942214720 @default.
- W2085687233 cites W1949815451 @default.
- W2085687233 cites W1964130299 @default.
- W2085687233 cites W1971731547 @default.
- W2085687233 cites W1980635119 @default.
- W2085687233 cites W1982123534 @default.
- W2085687233 cites W1985703111 @default.
- W2085687233 cites W1988070835 @default.
- W2085687233 cites W1992583586 @default.
- W2085687233 cites W1999330214 @default.
- W2085687233 cites W1999819978 @default.
- W2085687233 cites W2001068917 @default.
- W2085687233 cites W2001177765 @default.
- W2085687233 cites W2006398267 @default.
- W2085687233 cites W2011827928 @default.
- W2085687233 cites W2011963129 @default.
- W2085687233 cites W2014150894 @default.
- W2085687233 cites W2014280822 @default.
- W2085687233 cites W2018966815 @default.
- W2085687233 cites W2021242377 @default.
- W2085687233 cites W2022840517 @default.
- W2085687233 cites W2024166740 @default.
- W2085687233 cites W2024306318 @default.
- W2085687233 cites W2027850624 @default.
- W2085687233 cites W2033677399 @default.
- W2085687233 cites W2034286443 @default.
- W2085687233 cites W2037641660 @default.
- W2085687233 cites W2037729255 @default.
- W2085687233 cites W2038151584 @default.
- W2085687233 cites W2041572572 @default.
- W2085687233 cites W2047391267 @default.
- W2085687233 cites W2053850506 @default.
- W2085687233 cites W2057151285 @default.
- W2085687233 cites W2058099454 @default.
- W2085687233 cites W2063082801 @default.
- W2085687233 cites W2063550946 @default.
- W2085687233 cites W2066367871 @default.
- W2085687233 cites W2067882654 @default.
- W2085687233 cites W2068406884 @default.
- W2085687233 cites W2069023125 @default.
- W2085687233 cites W2071878999 @default.
- W2085687233 cites W2075256922 @default.
- W2085687233 cites W2077808289 @default.
- W2085687233 cites W2077812003 @default.
- W2085687233 cites W2089232394 @default.
- W2085687233 cites W2089564734 @default.
- W2085687233 cites W2093684206 @default.
- W2085687233 cites W2094855567 @default.
- W2085687233 cites W2115093096 @default.
- W2085687233 cites W2131207360 @default.
- W2085687233 cites W2133124453 @default.
- W2085687233 cites W2138807703 @default.
- W2085687233 cites W2140818834 @default.
- W2085687233 cites W2143052000 @default.
- W2085687233 cites W2157016693 @default.
- W2085687233 cites W2160662023 @default.
- W2085687233 cites W2167723688 @default.
- W2085687233 cites W2171575942 @default.
- W2085687233 cites W2293685045 @default.
- W2085687233 cites W2314938037 @default.
- W2085687233 cites W2321503226 @default.
- W2085687233 cites W2337577525 @default.
- W2085687233 cites W2400188205 @default.
- W2085687233 cites W2403474134 @default.
- W2085687233 cites W2411993397 @default.
- W2085687233 cites W2412205092 @default.
- W2085687233 cites W2414747178 @default.
- W2085687233 cites W4252805882 @default.
- W2085687233 cites W57149238 @default.
- W2085687233 cites W82416764 @default.
- W2085687233 doi "https://doi.org/10.1007/bf02782189" @default.
- W2085687233 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11114703" @default.
- W2085687233 hasPublicationYear "2000" @default.
- W2085687233 type Work @default.
- W2085687233 sameAs 2085687233 @default.
- W2085687233 citedByCount "14" @default.
- W2085687233 countsByYear W20856872332022 @default.
- W2085687233 crossrefType "journal-article" @default.
- W2085687233 hasAuthorship W2085687233A5005259160 @default.
- W2085687233 hasBestOaLocation W20856872331 @default.
- W2085687233 hasConcept C136449434 @default.